Shukra Pharmaceuticals Quarterly Results for Trading Insights
In Sept 2025, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹8 Cr and net profit ₹2 Cr. For annual financials, live price and key ratios, visit SHUKRAPHAR stock overview.
SHUKRAPHAR Quarterly Results — Revenue, Profit & EPS Highlights
Shukra Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with SHUKRAPHAR intrinsic value calculation to assess whether the stock is under or overvalued.
- Revenue of ₹8 Cr in Sept 2025 (-46.7% vs Mar 2025)
- Net Profit of ₹2 Cr in Sept 2025 (-60.0% vs Mar 2025)
- EBITDA of ₹1 Cr in Sept 2025 (-88.9% vs Mar 2025)
- Operating Margin of -7.0% in Sept 2025 (-62.0pp vs Mar 2025)
- Earnings Per Share of ₹0.05 in Sept 2025 (-58.3% vs Mar 2025)
Shukra Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SHUKRAPHAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8 | 15 | 7 | 40 | 12 | -46.7% | - |
| Net Profit (₹ Cr) | 2 | 5 | 1 | 20 | 3 | - | - |
| EBITDA (₹ Cr) | 1 | 9 | 2 | 28 | 5 | - | - |
| EPS (₹) | 0.05 | 0.12 | 0.02 | 0.47 | 0.72 | - | - |
| Operating Margin (%) | -7.0% | 55.0% | 24.0% | 69.0% | 37.0% | - | - |
SHUKRAPHAR Share Price Trend — 1-Year Movement Across Quarterly Results
Shukra Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse SHUKRAPHAR FII DII holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SHUKRAPHAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Shukra Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹396,418.12 Cr | 1652.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 127.1 |
|
Divis Laboratories
Sept 2025 |
₹162,373.86 Cr | 6070.0 | 2,860 | 689 | +7.1% | - | 24.1% | 233.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹140,630.85 Cr | 4181.0 | 3,219 | 591 | +11.3% | - | 18.4% | 238.4 |
|
Lupin
Sept 2025 |
₹106,664.75 Cr | 2315.1 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.5 |
|
Dr Reddys Laborator…
Sept 2025 |
₹102,844.71 Cr | 1235.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.4 |
All amounts in ₹ Crores